What is the dosing for Anti-Tuberculosis Treatment (ATT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Anti-Tuberculosis Treatment (ATT) Dosing Guidelines

The standard ATT regimen consists of isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E) for the initial 2 months, followed by isoniazid and rifampin for 4 months, with specific weight-based dosing for each medication. 1, 2

First-Line Drug Dosing for Adults

Daily Dosing (Preferred)

  • Isoniazid: 5 mg/kg (typically 300 mg) daily 1, 3
  • Rifampin: 10 mg/kg (typically 600 mg) daily 1
  • Pyrazinamide: 15-30 mg/kg daily (maximum 2g) 1, 4
  • Ethambutol: 15-25 mg/kg daily 1

Intermittent Dosing (Three times weekly)

  • Isoniazid: 15 mg/kg (typically 900 mg) 1, 3
  • Rifampin: 10 mg/kg (typically 600 mg) 1
  • Pyrazinamide: 30-40 mg/kg 1
  • Ethambutol: 25-35 mg/kg 1

First-Line Drug Dosing for Children

Daily Dosing

  • Isoniazid: 10-15 mg/kg daily 1, 2
  • Rifampin: 10-20 mg/kg daily 1, 2
  • Pyrazinamide: 35 mg/kg daily 1, 2
  • Ethambutol: 20 mg/kg daily 1, 2

Treatment Duration

The standard treatment duration for drug-susceptible pulmonary tuberculosis is 6 months:

  • Initial phase: 2 months of HRZE
  • Continuation phase: 4 months of HR 1

Special situations requiring longer treatment:

  • TB meningitis/CNS TB: 12 months (2 months HRZE + 10 months HR) 1
  • Bone/joint TB in children: 12 months 1
  • Military TB in children: 12 months 1

Treatment Categories

WHO categorizes TB treatment into four groups 1:

  1. Category I: New sputum smear-positive and other severe cases
  2. Category II: Retreatment cases
  3. Category III: New sputum smear-negative and non-severe extrapulmonary cases
  4. Category IV: Chronic cases

Retreatment Regimens

For previously treated patients who are more likely to have acquired drug resistance:

  • Initial phase: 5 drugs (SHRZE) for 2 months, followed by 4 drugs (HRZE) for 1 month
  • Continuation phase: 3 drugs (HRE) for 5 months 1

Fixed-Dose Combinations (FDCs)

FDCs are strongly recommended to improve adherence 1:

  • Rifamate®: Each capsule contains rifampin (300 mg) and isoniazid (150 mg); daily dose is two capsules 1
  • Rifater®: Each tablet contains rifampin (120 mg), isoniazid (50 mg), and pyrazinamide (300 mg); dosing based on weight 1

Special Considerations

Pregnancy

  • All drugs except streptomycin can be used during pregnancy
  • Pyridoxine (vitamin B6) 10-25 mg/day is recommended with isoniazid 1, 3

Renal Insufficiency

  • Dosage adjustments needed for ethambutol and streptomycin
  • Rifamate® may be used, but Rifater® should be avoided 1

Hepatic Disease

  • In patients with underlying hepatic disease, single-drug formulations are preferred until safety is established 1

HIV Co-infection

  • Standard regimens are effective but may require longer treatment
  • Monitor for drug interactions with antiretroviral therapy 1

Directly Observed Therapy (DOT)

DOT is strongly recommended to ensure adherence and prevent drug resistance 3. This involves:

  • Direct observation of medication intake by healthcare personnel
  • Can be administered daily or intermittently (3 times weekly)

Monitoring

  • Regular assessment of treatment response through clinical evaluation and sputum examinations
  • Monitor for adverse effects, especially hepatotoxicity
  • Adjust dosages with significant weight changes during treatment 2

Pitfalls to Avoid

  1. Inadequate initial regimen: Always include at least 4 drugs in the initial phase until susceptibility is confirmed
  2. Inappropriate intermittent therapy: Intermittent therapy should only be used with DOT
  3. Failure to adjust doses for weight: Recalculate doses with significant weight changes
  4. Overlooking drug interactions: Particularly important with rifampin
  5. Inadequate treatment duration: Shortened regimens have been shown to increase relapse rates 5

Remember that proper dosing and adherence to the full treatment course are essential to prevent treatment failure and development of drug resistance.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Pulmonary Tuberculosis in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.